Penumbra

PENUMBRA INC

Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.

ADMA

TMDX


While major market indexes like the S&amp;P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotechnology

3 Mid-Cap Medical Stocks Outperforming the Market

Penumbra, Inc

Analyst Color

Earnings

Large Cap

News

Guidance

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

Penumbra Q1 earnings beat estimates with strong sales and thrombectomy growth; analysts raise targets as company reaffirms 2025 guidance.

Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst

Konskie,,Poland,-,April,29,,2024:,Penumbra,Company,Logo,Displayed

Stroke Device Maker Penumbra Stock Surges On Earnings Beat, Analysts Boost Price Forecasts After Upbeat 2025 Outlook

Penumbra Inc

Pendle - United States Dollar

Penguin Solutions, Inc. - Ordinary Shares

Penguin Solutions Inc

Peninsula Energy Ltd

PENINSULA ENERGY LTD by Peninsula Energy Ltd.

PENN Entertainment Inc

PENTAMASTER CORP BHD by PENTAMASTER CORP BHD.

PENNANT INTL GRP PLC by Pennant International Group PLC

Press Releases

Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025

Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors

Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits

Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Penumbra, Inc. (NYSE: PEN)

Legal

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Penumbra, Inc. (NYSE: PEN) and Encourages Current Penumbra Shareholders to Contact the Firm

Penumbra, Inc. Reports First Quarter 2025 Financial Results

Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Comments

Penumbra

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell